Isomorphic Labs Raises $5 Billion, with a16z Joining
Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, has raised $5 billion in a Series C round. Greenoaks and Sequoia Capital co-led the round, and Andreessen Horowitz (a16z) joined as a new investor. The company announced the funding on 17 November and said it will use the money to scale its AI drug design platform and move its drug candidates toward clinical trials.
Alphabet, Isomorphic's parent company, invested again, as did Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose its valuation. Bloomberg reported on 4 November that the talks valued the company at about $50 billion.
Each round has been bigger than the last. Isomorphic took its first outside money, $600 million, in March 2025. Fourteen months later, a Thrive-led $2.1 billion Series B became the second-largest venture round ever raised by a biotech, behind Altos Labs' $3 billion in 2022. Six months after that, the Series C tops both and takes Isomorphic's external funding to about $7.7 billion.
Much of the new money will go to scaling IsoDDE, the company's AI drug design engine. The announcement also looks beyond design. Isomorphic plans to build its own AI-first translational and clinical development infrastructure to take candidates into trials, alongside new foundational biology models and AI-led bioengineering capacity.
Isomorphic says its pipeline is heading toward the clinic. Its internal programs in oncology and immunology, along with its partnered work, have produced positive preclinical results that set the stage for clinical entry. Its partners include Eli Lilly and Novartis, whose 2024 deals carry potential milestone payments of nearly $3 billion combined, as well as Johnson & Johnson.
Demis Hassabis, Isomorphic's founder and CEO, said the engine is now producing molecules with high precision and speed. Konstantine Buhler, a partner at Sequoia, called the company's work foundational technology for medicine.
For a closer look at how to judge Isomorphic's platform, see BiopharmaTrend's analysis The $50B Question: How Do We Know If Isomorphic's AI Works?
Topic: Biotech Ventures